Showing results (371-380 of 582) with videos related to

Sort By:
Pageof 59
Cardiovascular Drugs and Therapy|May 25, 2012
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trialMichael Davidson, Robert S Rosenson, Kevin C Maki, et al.
BMC Psychiatry|March 11, 2021
Acute day units for mental health crises: a qualitative study of service user and staff views and experiencesNicola Morant, Michael Davidson, Jane Wackett, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 26, 2019
Exposure to Antidepressant Medication and the Risk of Incident DementiaArad Kodesh, Sven Sandin, Abraham Reichenberg, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 18, 2024
Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolitionSydney H James, Anthony O Ahmed, Philip D Harvey, et al.
Biological Psychiatry|September 11, 2007
Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disordersMark Weiser, Abraham Reichenberg, Efrat Kravitz, et al.
Biological Psychiatry|September 18, 2003
Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophreniaMark Weiser, Abraham Reichenberg, Jonathan Rabinowitz, et al.
Innovations in Clinical Neuroscience|June 18, 2020
Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo?David G Daniel, Alan Kott, Jay Saoud, et al.
Lung Cancer (Amsterdam, Netherlands)|May 9, 2021
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondKroopa Joshi, Abdul Muhith, Mariam Obeid, et al.
JAMA Psychiatry|November 26, 2015
Developmental Trajectories of Impaired Community Functioning in SchizophreniaEva Velthorst, Abraham Reichenberg, Ori Kapra, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|August 19, 2025
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze, Timo Schurr, Fabienne Post, et al.
Pageof 59